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Polyreactive antibodies bind to a variety of
structurally unrelated antigens. The function of
these antibodies, however, has remained an
enigma, and because of their low binding
affinity their biological relevance has been
questioned. Using a panel of monoclonal poly-
reactive antibodies, we showed that these anti-
bodies can bind to both Gram-negative and
Gram-positive bacteria and acting through the
classical complement pathway can inhibit bac-
terial growth by lysis, generate anaphylatoxin
C5a, enhance phagocytosis, and neutralize
the functional activity of endotoxin. Polyreac-
tive antibody-enriched, but not polyreactive
antibody-reduced, IgM prepared from normal
human serum displays antibacterial activity
similar to that of monoclonal polyreactive IgM.
We conclude that polyreactive antibodies are
a major contributor to the broad antibacterial
activity of the natural antibody repertoire.
INTRODUCTION
What are now known as natural antibodies were first de-
scribed nearly 100 years ago (Tauber and Podolsky,
1997). Innumerable studies since have shown that serum
containing these antibodies has bactericidal activity, and
in fact, to distinguish antigen-induced antibodies from
natural antibodies, serum is routinely diluted 10- to
50-fold before testing to reduce the background activity
of the natural antibodies (Notkins, 2004). Natural anti-
bodies, however, have remained an enigma to immunolo-
gists because they are found in serum in the apparent
absence of antigenic stimulation and are present in
newborns and germ-free animals. Absorption of serum
with a specific protein or bacterium can result in the loss
of antibody activity not only to the antigen used for ab-
sorption, but also to other unrelated proteins or bacteria
(Gordon and Carter, 1932; Michael et al., 1962). AddingCellfurther to the enigma of natural antibodies is the observa-
tion that many natural antibodies react with a variety of
normal host proteins, suggesting that some of these anti-
bodies are autoantibodies, which would seem to contra-
dict the well-accepted view that the host is immunologi-
cally tolerant of most self antigens. The fact that normal
serum contains millions of different Ig molecules, all in
small quantities, has made it difficult to characterize these
antibodies.
With the advent of hybridoma technology in the mid-
1970s, it became possible to prepare large quantities of
individual Ig molecules. Analysis of these monoclonal Ig
molecules, prepared from normal individuals, revealed
that many were polyreactive; that is, they could bind to
a variety of structurally unrelated self (e.g., proteins, lipids,
carbohydrates, DNA) and nonself (e.g., bacteria, viruses)
antigens (Haspel et al., 1983; Dighiero et al., 1983; Casali
and Notkins, 1989; Prabhakar et al., 1984; Burastero et al.,
1988). These polyreactive antibodies bind to antigens with
low affinity (Kd = 103 to 107 mol l1) as compared to
monoreactive antibodies (Kd = 107 to 1011 mol l1),
and each polyreactive antibody has a distinct antigen-
binding pattern that can vary for different antigens by as
much as 1000-fold (Haspel et al., 1983; Dighiero et al.,
1983; Casali and Notkins, 1989; Prabhakar et al., 1984;
Burastero et al., 1988). Many of the polyreactive anti-
bodies have a germline or near-germline sequence and
are primarily IgM, but some are also IgG and IgA. Contrary
to the classic ‘‘lock and key’’ rigid-structure hypothesis of
antigen-antibody interaction, the antigen-binding pocket
of polyreactive antibodies, perhaps because of their
germline configuration, are believed to be more flexible
and therefore can accommodate different antigenic con-
figurations (Notkins, 2004). The B cells that make these
antibodies can be identified by the binding of fluores-
cein-labeled antigens to the polyreactive B cell receptors
on their surface (Zhou and Notkins, 2004; Wang et al.,
2001). Some of those polyreactive antigen-binding B
(PAB) cells have a B-1-positive, whereas others have a
B-1-negative, phenotype (Zhou and Notkins, 2004). In the
newborn up to 50% of peripheral blood B lymphocytes
can make polyreactive antibodies. In the adult the number
is reduced to between 15% and 20% (Chen et al., 1998).Host & Microbe 1, 51–61, March 2007 ª2007 Elsevier Inc. 51
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Antibacterial Activity of Polyreactive AntibodyFigure 1. Properties of Polyreactive Antibody 2E4
(A) Dose-dependent binding of 2E4 to different antigens as measured by ELISA and the calculated dissociation constants (Kd).
(B) Polyreactive antibody 2E4 (red line) binds to a variety of Gram-positive and Gram-negative bacteria.
(C) Nonpolyreactive MAb2507 (red line) only binds to its cognate antigen, E. coli O157: H7.
(D) Polyreactive antibody 2E4 (right panel), but not nonpolyreactive MAb2507 (left panel), fixes complement as measured by FACS analysis with
anti-C3.
So, S. oralis; Sm, S. mitis; Sg, S. gordonii; An, A. naeslundii; Ec, E. coli.Polyreactive antibodies therefore are a major component
of the natural antibody repertoire.
Natural antibodies have long been thought to be a first
line of defense against bacterial and viral infections (Casali
andNotkins, 1989), but the biological function of polyreac-
tive antibodies has never been determined. In fact, be-
cause of their low affinity their biological relevance has
been questioned. The present experiments were initiated
to determine whether polyreactive antibodies have anti-
bacterial activity.
RESULTS
Properties of Polyreactive Antibody 2E4
Mouse hybridomas were prepared, cloned, and screened
for polyreactivity. Polyreactive antibody 2E4 was chosen
for detailed study. Of the antigens screened the strongest
binding was to ssDNA and b-gal with weaker binding to52 Cell Host & Microbe 1, 51–61, March 2007 ª2007 Elsevier Ininsulin, Tg, and LPS (Figure 1A). The dissociation con-
stants (Kd) for ssDNA, b-gal, and insulin were 4.0 3
108, 7.03107, and 1.03105, respectively. As with
other polyreactive antibodies (Haspel et al., 1983), 2E4
bound to a variety of organs and cell types as determined
by indirect immunofluorescence (data not shown). Gene
sequencing revealed that 2E4 is an IgM antibody with
a germline sequence that is 99.7% identical to J558.8
(Table S1 in the Supplemental Data available with this
article online).
Polyreactive Antibody 2E4 Binds to a Variety
of Different Bacteria
The binding of 2E4 to a variety of Gram-positive and
Gram-negative bacteria, including different serotypes of
three antigenically distinct genera, was determined by
FACS analysis. Representative data (Figure 1B) show
that 2E4 binds strongly to some bacteria (Streptococcusc.
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Antibacterial Activity of Polyreactive AntibodyFigure 2. Polyreactive 2E4 Is Bactericidal in the Presence of Complement
(A and B) Growth of 2E4-treated E. coli BL21 as measured by the incorporation of 3H-TdR in the presence of different concentrations of untreated (A)
and heat-inactivated (B) complement.
(C) Bacteria colony formation on agar plates in the presence of complement with or without 2E4.
(D) Lysis of 2E4-treated bacteria as measured by the release of 3H-TdR in the presence of different concentrations of complement.
(E and F) Growth of 2E4-treated bacteria as determined by the incorporation of 3H-TdR in the presence of different concentrations of C4+/+ or C4/
serum (E) or heat-inactivated C4+/+ or C4/ serum (F).
(G) Lysis of 2E4-treated E. coli BL21 as measured by the release of 3H-TdR in the presence of different concentrations of C4+/+ or C4/ serum.
Bars represent SD.oralis J22, Streptococcus oralis 10557, Streptococcus mi-
tis 15914, and E. coli BL21), moderately to other bacteria
(Streptococcus oralisC104, Streptococcus oralis 34, Acti-
nomyces naeslundii T14V, and E. coli K12), and weakly or
not at all to still other bacteria (Streptococcus gordonii 38,
Streptococcus gordonii DL1, Actinomyces naeslundii
12104, and E. coli O157: H7). In contrast, monoclonal an-
tibodyMAb2507 reacted only to its cognate antigen E. coli
O157: H7 (Figure 1C).
Polyreactive Antibody 2E4 Fixes Complement
and Inhibits E. coli Growth
Bacteria (E. coli BL21) that had been incubated with poly-
reactive antibody 2E4 or the nonbinding monoreactive an-
tibody MAb2507 were incubated with complement. The
fixation of complement was determined by FACS analysis
with an antibody to the third component of complement
(C3). As seen in Figure 1D, complement bound strongly
to the polyreactive antibody-treated bacteria, but not to
the nonbinding monoreactive antibody-treated bacteria.CellThe effect of complement on the growth of bacteria
treated with polyreactive antibody 2E4 was determined
by measuring the incorporation of 3H-thymidine. At
a 1:10 dilution of complement, there was little if any in-
corporation of 3H-thymidine into bacteria as compared
to bacteria that had been treated with PBS or with
MAb2507 (Figure 2A). At higher dilutions of complement
the growth-inhibitory effect decreased, and with heat-in-
activated complement (Figure 2B) there was no inhibition
of growth.
The inhibitory effect of 2E4 and complement also was
demonstrated by plating the 2E4-treated and untreated
bacteria on agar plates and evaluating the number and
size of the bacterial colonies. Bacteria treated with 2E4
and complement showed little if any colony formation as
compared to bacteria treated with PBS and complement
(Figure 2C).
To determine if the inhibition of growth was due to bac-
terial lysis, the release of 3H-TdR from radiolabeled E. coli
BL21 was measured. Figure 2D shows that considerablyHost & Microbe 1, 51–61, March 2007 ª2007 Elsevier Inc. 53
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Antibacterial Activity of Polyreactive AntibodyFigure 3. Lysis ofPseudomonas aeruginosa by Polyreactive Antibody 2E4 andE. coliBL21 by Polyreactive Antibodies ZH-6, ZH-14,
and ZH-20 in the Presence of Complement
(A) PAb2E4, but not MAb8512, binds to Pseudomonas aeruginosa (PSA-10).
(B) Enhanced lysis of 2E4-treated PSA-10 as compared to MAb8512-treated PSA-10 in the presence of two different concentrations of complement
as measured by the release of 3H-adenine.
(C) Polyreactive antibodies ZH-6, ZH-14 and ZH-20, but not nonpolyreactive MAb2507, bind to E. coli BL21.
(D) Inhibition of growth of antibody-treated E. coli BL21 as measured by incorporation of 3H-TdR in the presence of complement (left) or heat-
inactivated complement (right).
(E) Lysis of antibody-treated E. coli BL21 as measured by the release of 3H-TdR in the presence of complement.
Error bars represent SD.more 3H-TdR was released from the cells treated with 2E4
than those treated with MAb2507 or PBS and that the
effect was complement dependent.
Bactericidal Activity of 2E4 Is Mediated
through the Classical Complement Pathway
The classical complement pathway, in contrast to the al-
ternative complement pathway, is antigen-antibody spe-
cific and requires C4 (Carroll, 2004). To see if polyreactive
2E4 exerted its growth-inhibitory effect through the classi-
cal complement pathway, C4/ serum was compared to
C4+/+ serum as a source of complement. Figure 2E shows
that the growth of 2E4-treated bacteria, as measured by54 Cell Host & Microbe 1, 51–61, March 2007 ª2007 Elsevierthe uptake of 3H-TdR, wasmarkedly inhibited byC4+/+ se-
rum, but not by C4/ serum or by heat-inactivated C4+/+
serum (Figure 2F). Release of 3H-TdR from radiolabeled
2E4-treated bacteria by C4+/+ serum, but not by C4/
serum, showed that the inhibition of growth was due to
bacterial lysis mediated through the classical complement
pathway (Figure 2G).
Polyreactive Antibody 2E4 Binds to and Lyses
Pseudomonas aeruginosa
To see if polyreactive antibody 2E4 would inhibit the
growth of other bacteria, Pseudomonas aeruginosa sero-
type 10 (PSA-10), was chosen for study. Figure 3A showsInc.
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Polyreactive antibodies in the presence of
complement do not lyse Gram-positive bacte-
ria (i.e., Streptococcus mitis, Streptococcus
oralis) but generate the anaphylatoxin C5a.
(A) Polyreactive antibody 2E4 (black line) fixes
complement as measured by FACS analysis
with anti-C3 antibody as compared to non-
binding MAb8512 (gray shadow).
(B) Neither polyreactive 2E4-treated nor non-
polyreactive MAb8512-treated Gram-positive
bacteria are lysed in the presence of comple-
ment (1:10 dilution) as determined by 3H-TdR
release.
(C) Monoclonal antibody-treated Gram-posi-
tive bacteria were incubated with guinea pig
complement (1:10 dilution) followed by incuba-
tion with human C5. PAb2E4-treated, but not
MAb8512-treated, Gram-positive bacteria
generated anaphylatoxin C5a as measured
by ELISA.
Error bars represent SD.that 2E4 binds to PSA-10 as demonstrated by FACS anal-
ysis and fixes complement (data not shown). In the pres-
ence of complement, polyreactive antibody 2E4, but not
nonpolyreactive MAb8512, produced significant lysis of
PSA-10 (Figure 3B).
Other Monoclonal Polyreactive Antibodies
with Antibacterial Activity
Three additional monoclonal polyreactive antibodies were
prepared and tested (Table S1). Monoclonal antibody ZH-
6 and ZH-20 were IgMs, belonged to the J558 family, and
were 100% and 99.3% identical to J558.2 and J558.13,
respectively. Their light chains belonged to the VK-21 fam-
ily and the VK-12 family, respectively. In contrast, ZH-14
was an IgG3, belonged to the VGAM3.8 (VH9) family,
and was 96.8% identical to VH9.1. The light chain be-
longed to the VK-21 family. These antibodies then were
tested for their binding to a variety of antigens and bacte-
ria. In contrast to 2E4 (Figure 1B), all three antibodies
showed an intermediate level of binding to E. coli BL21
(Figure 3C), but in the presence of complement the three
antibodies inhibited the growth of E. coli (Figure 3D), which
was mediated through bacterial lysis (Figure 3E).
Generation of Anaphylatoxin C5a in the Absence
of Bacterial Lysis
Polyreactive antibody 2E4 can bind to a variety of Gram-
positive bacteria (Figure 1B) and also fix complement
(Figure 4A). However, in contrast to Gram-negative bacte-
ria, Gram-positive bacteria are not lysed (Figure 4B), nor is
their growth inhibited (data not shown). Despite the failureCeto inhibit growth, the interaction of polyreactive antibodies
with Gram-positive bacteria, in the presence of comple-
ment, generates solid phase C5 convertase and, in turn,
the anaphylatoxin C5a, an important chemotaxis factor
(Figure 4C).
Polyreactive MAb2E4 Enhances Phagocytosis
The fixation of complement to antigen-antibody com-
plexes can enhance phagocytosis. Bacteria E. coli BL21
were labeled with FITC, treated with polyreactive 2E4 or
nonbinding MAb2507, and then incubated with comple-
ment. Phagocytosis of the bacteria by mouse macro-
phages was evaluated by confocal microscopy and
FACS analysis. As seen in Figure 5A, bacteria treated
with polyreactive 2E4 and complement were readily
phagocytosed as compared to bacteria treated with non-
binding MAb2507 and complement or with 2E4 alone or
complement alone (Figure 5B). Maximum fluorescence
(phagocytosis) was detected at 150 min.
Polyreactive Antibodies Neutralize the Functional
Activity of Endotoxin
Exposure of human monocytes to endotoxin (LPS) re-
sulted in the production of matrix metalloproteinase 1
(MMP-1) (Zhang et al., 1997). Incubation of LPS from Sal-
monella abortus-equi (SAE) with polyreactive antibody
MAb2E4, but not irrelevant MAb8512, reduced the
production of MMP-1 (Figure 5C). Similar results were
obtained with three other polyreactive antibodies (i.e.,
ZH-14, ZH-6, and ZH-20) using LPS from three different
bacteria (i.e., SAE, E. coli O157: H7 and PSA) (Figuresll Host & Microbe 1, 51–61, March 2007 ª2007 Elsevier Inc. 55
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Antibacterial Activity of Polyreactive AntibodyFigure 5. Polyreactive Antibodies En-
hance Phagocytosis and Inhibit the
Activity of LPS
(A) Immunofluorescence staining shows bac-
teria E. coli BL21 (green) being taken up by
macrophages (red) with blue nuclei. Left panel:
bacteria treated with MAb2507 and comple-
ment. Right panel: bacteria treated with
PAb2E4 and complement.
(B) Phagocytosis of 2E4-treated bacteria in the
presence of complement, as determined by
FACS analysis and measured by mean fluo-
resce intensity (MFI).
(C) Human monocyte MMP-1 is increased by
incubation with LPS (Salmonella abortus-equi
[SAE]) in the presence of PBS or nonbinding
MAb8512 but is decreased by polyreactive
2E4.
(D) MMP-1 is not produced by monocytes in-
cubated with PBS or with different polyreactive
(i.e., ZH-14, ZH-6, and ZH-20) or nonpolyreac-
tive MAbs (i.e., 8512 and 2507) in the absence
of LPS.
(E–G) Monocyte MMP-1 production is in-
creased by incubation with LPS from SAE (E),
E. coli O157: H7 (F), or Pseudomonas aerugi-
nosa (PSA) (G) in the presence of PBS or non-
binding MAb8512 but is decreased by poly-
reactive MAbs ZH-14, ZH-6, and ZH-20.
Nonpolyreactive MAb2507 decreased only
the production of MMP-1 induced by LPS
from E. coli O157: H7, its cognate antigen (F).
(H) Polyreactive-enriched, but not polyreac-
tive-reduced, human IgM inhibits LPS-induced
production of MMP-1.5E–5G). MAb2507 reduced only the production of MMP-1
by LPS from Ec-O157: H7, its cognate antigen (Fig-
ure 5F), but not the production of MMP-1 by LPS from
SAE or PSA (Figures 5E and 5G). None of the monoclonal
antibodies bound directly to monocytes as evaluated by
immunostaining and FACS analysis (data not shown).
These findings show that polyreactive antibodies can
neutralize the functional activity of LPS in the absence of
complement.
Polyreactive Antibodies from SerumAre Bactericidal
Polyreactive antibodies from normal serum were enriched
by serial passage of affinity-purified human IgM through
three different antigen-affinity columns (i.e., ssDNA,
b-gal, thyroglobulin). The polyreactive-enriched, as com-
pared to the polyreactive-reduced, IgM bound to a variety
of different antigens (Figure 6A), including bacteria
(Figure 6B), and in the presence of complement lysed
radiolabeled E. coli BL21 (Figure 6C). In the absence of
complement, polyreactive-enriched, but not polyreac-
tive-reduced, human IgM decreased the production of
LPS-induced MMP-1 (Figure 5H). These findings show
that polyreactive antibodies from human sera have anti-
bacterial properties similar to monoclonal polyreactive
antibodies.56 Cell Host & Microbe 1, 51–61, March 2007 ª2007 ElsevierDISCUSSION
Natural antibodies, by definition, are produced in the
apparent absence of antigenic stimulation (Tauber and
Podolsky, 1997). The most likely explanation for their
occurrence is that they are the result of the millions of nor-
mally occurring VDJ rearrangements and exist in germline
or near-germline configuration. Because of their diversity,
the percentage of antibodies in normal serum that are pol-
yreactive has been difficult to determine. However, since
up to one-half of the B cells in the cord blood of newborns
and one-fifth of the B cells in the peripheral circulation of
adult are capable of making polyreactive antibodies, it is
evident that these antibodies are highly represented
(Chen et al., 1998; Wardemann et al., 2003).
The high representation of polyreactive antibodies rai-
ses questions about the nature and function of the non-
polyreactive antibodies in the natural antibody repertoire.
Assuming that they too exist in germline or near-germline
configuration, it is unclear whether they have sufficient
specificity and affinity to be biologically relevant in natural
defense against invading pathogens without further anti-
genic stimulation and somatic mutation. If, in fact, the
genes encoding these nonpolyreactive antibodies are
not in germline configuration and instead show many so-
matic mutations, they rightfully should not be consideredInc.
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Antibacterial Activity of Polyreactive Antibodypart of the natural antibody repertoire. Perhaps more
important, even if some of these germline-encoded non-
polyreactive antibodies do have a potential biological
function, their concentration in serum as an individual mo-
lecular species may be too low to have immediate biolog-
ical value when confronted with invading pathogens.
In contrast to nonpolyreactive antibodies, the great
number and diversity of polyreactive antibodies, with the
ability of many of them to recognize the same bacteria
and multiple antigens on those bacteria, make them a
major component of the natural antibody repertoire and
Figure 6. Bactericidal Activity of Polyreactive Antibody-
Enriched Human IgM
(A and B) Binding of polyreactive antibody-enriched, as compared to
polyreactive antibody-reduced, IgM to different antigens (A) and to
E. coli BL21 (B).
(C) Polyreactive-enriched, but not polyreactive-reduced, IgM lyses
E. coli BL21 in the presence of complement as measured by the re-
lease of 3H-TdR. Equal concentrations (50 mg/ml) of polyreactive-
enriched and polyreactive-reduced IgM were used in all experiments.
Error bars represent SD.Celpotentially an important first line of defense. This is not
meant to negate the possibility that there may be a popu-
lation of germline-encoded nonpolyreactive natural anti-
bodies directed against evolutionally conserved epitopes
found on pathogens such as phosphocholine (Briles et al.,
1981; Claflin and Berry, 1988). In fact, such antibodies
have been found by hybridoma technology, but in many
cases it was not clear whether these antibodies were
monoreactive, oligoreactive, or polyreactive (Notkins,
2004); truly encoded by germline sequences; or presented
in sufficient concentration in the serum to have biological
value.
Polyreactive antibodies are an ancient part of the im-
mune system and have been found in jawed vertebrates
going back as far as the shark (Marchalonis et al., 2001;
Marchalonis et al., 2002). The ability of polyreactive anti-
bodies to bind to a variety of different antigens suggests
that these antibodies represent the humoral component
of the innate immune system. In fact, upon entering the
host, pathogens will be exposed almost immediately to
polyreactive antibodies, since these antibodies are con-
stantly present in serum. This exposure, in the presence
of complement, could result in lysis of bacteria, which in
turn could lead to the release of ligands (e.g., CpG-DNA)
that bind to Toll-like receptors. In this way the innate
immune system could be activated (Krieg, 2002). Of par-
ticular interest is the fact that, even though the interaction
of polyreactive antibodies with Gram-positive bacteria
does not result in lysis, it does activate the complement
cascade. Cleavage products such as C5a then bind to
a whole range of cell surface receptors on myeloid and
lymphoid cells and thereby contribute to the host’s inflam-
matory response (Guo andWard, 2005; Huber-Lang et al.,
2006). Thus the initial encounter of polyreactive antibodies
with pathogens could serve as a first line of defense and
give the adaptive immune system time to be activated.
A variety of studies involving the passive transfer of nor-
mal serum to animals that subsequently were challenged
with bacteria or viruses showed that normal serum en-
hanced protection (Ochsenbein et al., 1999; Baumgarth
et al., 2000; Quan et al., 1997; Kroese et al., 1996; Boes
et al., 1998). To what extent this protection was due to
the polyreactive antibodies in the transferred serum, how-
ever, has never been determined. The demonstration here
that both monoclonal polyreactive antibodies and en-
riched, but not reduced, polyreactive antibodies prepared
from normal serum can lyse bacteria, generate C5a, en-
hance phagocytosis, and neutralize endotoxin argues
that polyreactive antibodies contribute in an important
way to the antibacterial activity of normal serum. The
effectiveness of polyreactive antibodies depends on the
nature of the antigens on the particular pathogen and
the titer and binding capacity of the circulating polyreac-
tive antibodies.
In addition to their role in defense, a variety of other
functions have been attributed to natural antibodies, in-
cluding clearance of degraded proteins (e.g., red blood
cells, bacteria), the enhancement of immunogenicity
by trapping of antigens in lymphoid organs, andl Host & Microbe 1, 51–61, March 2007 ª2007 Elsevier Inc. 57
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pir and Shoenfeld, 2005; Miller and Rodriguez, 1995;
Trebst and Stangel, 2006; Robey et al., 2002). In none of
these cases, however, has the role of polyreactive anti-
bodies been evaluated. It is of particular interest that the
intravenous administration of natural Ig (IVIG) is being
used to treat a variety of disorders (Sapir and Shoenfeld,
2005; Siragam et al., 2006). There is no consensus as to
how natural Ig works, but again the role of polyreactive an-
tibodies needs to be evaluated.
Although polyreactive antibodies can bind to normal
mammalian tissues, under ordinary circumstances, they
do not appear to be deleterious to the host, presumably
because a variety of regulatory proteins (e.g., factor H,
DAF, CR-1) inhibit the lytic action of complement on eu-
karyotic cells (Zipfel, 2001; Kinoshita et al., 1985; Wagner
et al., 2006). Moreover, it is well established that B cells
capable of making high-affinity self-reactive antibodies
are eliminated from the host early in life by negative selec-
tion, but because of their low affinity, there may be little
need for the host to eliminate the B cells that make poly-
reactive antibodies. In fact, because of their low affinity
and germline configuration, polyreactive antibodies do
not appear to be true autoantibodies and certainly do
not fit into the same category as antigen-specific, somat-
ically mutated, high-affinity pathogenic autoantibodies
(Brard et al., 1999; Roark et al., 2002; Rahman, 2004;Well-
mann et al., 2005). It is possible, however, that the B cells
that make polyreactive antibodies might be the precursor
population from which at least some high-affinity autoan-
tibodies are derived (Ichiyoshi et al., 1995). There also is
some evidence that the polyreactive B cell population
may be the result of positive selection. Transgenic mouse
models provide support for the positive-selection hypoth-
esis (Julien et al., 2002; Hayakawa et al., 2003;Wong et al.,
2002; Hardy and Hayakawa, 2005; Gaudin et al., 2004;
Casola et al., 2004), but which self antigens are involved
in positive selection of polyreactive B cells is still not clear.
In conclusion, the demonstration that passive transfer
of normal sera containing natural antibodies can enhance
resistance to bacteria and viruses (Ochsenbein et al.,
1999; Boes et al., 1998; Reid et al., 1997) and the demon-
stration here of the antibacteria, antitoxin (i.e., LPS), and
phagocytosis-enhancing effects of polyreactive anti-
bodies raise the intriguing, although still distant, possibility
that passive administration of a cocktail of monoclonal
polyreactive antibodies might prove useful in the preven-
tion and treatment of some infections. If this turns out to
be the case, developing methods to activate in vivo the
B cell subset that makes polyreactive antibodies might
be of value in broadly enhancing natural resistance during
times of bacterial and viral epidemics.
EXPERIMENTAL PROCEDURES
Mice, Cell Lines, and Bacterial Strains
Three- to twelve-week-old BALB/c mice were bred at the NIH animal
facility (Bethesda, MD). All experiments were carried out in compliance
with institutional guidelines and approved by the NIDCR ACUC58 Cell Host & Microbe 1, 51–61, March 2007 ª2007 Elsevier Inc(Bethesda, MD). Gram-negative E. coli bacteria were cultured in
Luria-Bertani (LB) broth, Pseudomonas aeruginosa Migula serotypic
10 (PSA-10) were cultured in Nutrient broth (BD234000), and different
Gram-positive bacteria (i.e., S. gordonii, S. oralis, S. mitis, and A.
naeslundii) were cultured in Todd Hewitt broth (Krackeler Scientific,
Inc., Albany, NY) until an OD600 of 0.3 was reached. Mouse macro-
phage cell line Raw264.7 was cultured in RPMI1640 with 10% FBS
and replaced with serum-free medium before use.
Preparations of Hybridomas
Splenocytes were isolated from 3- to 12-week-old BALB/c mice and
fused with Sp2/0-Ag14 myeloma cells (Hartman et al., 1989). Positive
clones were subcloned by limiting dilution at least two times. Large
amounts of antibody were prepared by culturing hybridoma cells in
serum-free CD Hybridoma Medium (Invitrogen, Carlsbad CA). Super-
nates were concentrated and quantitated by Coomassie Plus Protein
Assay Kit (Pierce Biotechnology, Inc, Rockford, IL). In the current
study, four new monoclonal polyreactive antibodies (2E4, ZH-6,
ZH-14, and ZH-20) were prepared and characterized (Table S1). Two
monoclonal monoreactive mouse IgM antibodies (2507 and 8512)
were obtained from ATCC (ATCC no. CRL-2507, HB-8512) and used
as controls. 2507 is specific for E. coli O157: H7 O-antigen, and
8512 is against bacterial cell wall peptidoglycan.
RT-PCR and Sequencing of Variable Regions
of Immunoglobulins
Total RNA from hybridomas was isolated with TRIZOL (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol, and the con-
stant and variable regions of IgM and IgGwere amplified by PCR using
Mouse Ig-Primer Sets from Novagen (EMD Biosciences, Inc., La Jolla,
CA). PCR fragments were cloned in pCR2.1 vector (Invitrogen) and
sequenced.
ELISA and Affinity Assays
Approximately 10 mg/ml of antigens (b-galactosidase, thyroglobulin,
insulin, ssDNA, lipopolysacride, etc.) (Sigma, St. Louis, MO) in coating
buffer (15 mM Na2CO3, 35 mM NaHCO3) were adsorbed onto Maxi-
sorp microplates (Nalge Nunc, Copenhagen, Denmark). Nonspecific
binding sites were blocked by incubation with 1% BSA in phos-
phate-buffered saline (PBS). Different concentrations of purified
monoclonal antibody were loaded in wells. The second antibody
(biotin-labeled rat anti-mouse IgM or biotin-labeled polyclonal goat
anti-mouse Igs at 2 mg/ml) (BD Pharmigen, San Diego, CA) then was
added. The reaction mixture was developed with Avidin-HRP (1:3000
dilution) and ABTS substrate (Zymed Laboratories, South San Fran-
cisco, CA), and absorbance was read at 415 nm by an Elisa microplate
reader (Molecular Devices Corporation, Sunnyvale, CA). Affinity
assays were performed as described (Nakamura et al., 1988) by com-
petitive ELISA, and the dissociation constants (Kd) were calculated
according to Friguet et al. (1985).
Affinity Isolation of Human Polyreactive IgM
Affinity columns of ssDNA, b-gal, and thyroglobulin were preparedwith
HiTrap NHS-activated HP columns (GE Healthcare, Piscataway, NJ)
according to the manufacturer’s instruction. Purified human IgM
(>96% purification) isolated from normal human serum was obtained
from Research Diagnostics, Inc., Flanders, NJ. Human IgM was
sequentially passed through and eluted from DNA, b-gal, and thyro-
globulin columns. The pass-through fractions were designated ‘‘poly-
reactive IgM-reduced’’ and the eluted fractions ‘‘polyreactive IgM-
enriched.’’ IgM was eluted by washing with 2 M NaCl and desalted
with HiTrap Desalting columns (GE Healthcare). The polyreactive-
enriched and polyreactive-reduced IgM fractions were concentrated
by Macrosep centrifugation (Pall Life Sciences, Ann Arbor, MI), and
the protein concentration was determined by Coomassie Plus Protein
Assay Kit (Pierce Biotechnology, Inc., Rockford, IL)..
Cell Host & Microbe
Antibacterial Activity of Polyreactive AntibodyImmunofluorescence Staining and Flow Cytometry Assays
To measure the binding of antibody, 2 3 107 bacteria or 3.0 to 4.0 3
105 mammalian cells were preincubated with 1% BSA and 2 mM
EDTA at 4C for 30 min to minimize the effect of nonspecific binding
sites. Mammalian cells also were preincubated with 20 mg/ml Mouse
Fc Block (BD PharMingen). The cells then were incubated with mouse
monoclonal polyreactive or monoreactive antibodies (50 mg/ml)
followed by FITC-labeled goat anti-mouse IgM (Sigma-Aldrich Inc,
St. Louis, MO) and fixed with 4% paraformaldehyde. Unless indicated
otherwise, to measure the binding of complement, antibody-treated
bacteria were incubated with 1:15 dilution of guinea pig complement
serum (Cedarlane Laboratories Limited, Ontario, Canada) that had
been preadsorbed by four rounds of incubation with the bacteria to
be tested to eliminate bacteria-binding immunoglobulin that might
be present in the guinea pig serum. This was followed by incubation
with FITC-labeled goat anti-guinea pig C3 polyclonal antibody
(VitroStat Inc., Portland, ME) and fixation with 4% paraformaldehyde.
Fluorescence intensity was analyzed by FACSCalibur using CELL
Quest software (BD, San Jose, CA).
Bacterial Growth
Bacteria (23 107) were treated with 50 mg/ml polyreactive or nonpoly-
reactive antibodies or PBS, followed by incubation with different
dilutions of bacterial adsorbed guinea pig complement serum (to elim-
inate bacteria-binding Ig) at 37C for 1 hr. Incorporation of [3H]TdR or
[3H]adenine (20 mCi/ml) (GE Healthcare) was used tomeasure bacterial
growth. At different time points, 100 ml of medium containing bacteria
was removed, placed in triplicate on 0.45 mm filters of a 96-well filtra-
tion plate (Millipore, Bedford, MA), and washed eight times, and the
amount of radioactivity remaining on the filters was determined
(Microbeta 1450 Trilux liquid scintillation counter, Wallac, Gaithers-
burg, MD). Growth also was determined by seeding 1:1000 dilution
of bacterial cultures onto LB-agar plates, and colonies were counted
after overnight incubation at 37C. All experiments were repeated at
least three times.
Bactericidal Assay
E. coli were radiolabeled by culturing in LB broth with 20 mCi/ml
[6-3H]Thymidine (GE Healthcare), and PSA-10 were radiolabeled by
culturing in nutrient broth (BD234000) with 20 mCi/ml [8-3H]adenine
(GE Healthcare). Radio-labeled bacteria (3 3 107), suspended in
PBS-BSA, then were incubated with polyreactive or nonpolyreactive
monoclonal antibodies (50 mg/ml) to which was added different dilu-
tions of bacterial adsorbed guinea pig complement or bacterial
adsorbed C4/ guinea pig serum (to eliminate bacteria-binding Ig).
After incubation at 37C for 1 hr, the reactionmixtures were transferred
to 96-well filtration plates (Millipore) and washed, and the cpm remain-
ing on the filters was determined with a Microbeta 1450 Trilux liquid
scintillation counter. Percent lysis was calculated as [(cpm of bacteria
treated with control sera)  (cpm of bacteria treated with polyreactive
antibody)/(cpm of bacteria treated with control sera)] 3 100.
Measurement of C5a
Gram-positive bacteria (2 3 107) were incubated with polyreactive or
nonpolyreactive monoclonal antibodies, followed by incubation with
1:10 dilution of guinea pig complement as described above. The
bacteria then were washed twice and incubated with 10 mg/ml of
complement C5 from human serum (Sigma) at 37C for 1 hr. Genera-
tion of C5a was determined by human C5a ELISA kit (BD Bioscience,
San Jose CA).
Opsonization of Bacteria
Bacteria were labeled with FITC using a FluoroTag FITC conjugation kit
purchased from Sigma (St. Louis, MO) as described by Weingart et al.
(1999). The FITC-labeled bacteria then were incubated with mono-
clonal polyreactive or nonpolyreactive antibodies or PBS for 30 min,
washed, and incubated with 1:15 dilution of bacterial adsorbed guinea
pig complement for 30 min. The bacteria then were added toCeRaw264.7 macrophages cultured in 24-well plates with serum-free
medium. At different time points, the cells were trypsinized and fixed
with 4% paraformaldehyde, and mean fluorescence intensity deter-
mined. Raw264.7 macrophages also were cultured on Lab-Tek Cham-
bered Coverglass (Nunc, Inc. Naperville, IL). The nuclei of Raw264.7
macrophages were prestained (blue) by culturing in 10 mg/ml of
Hoechst 33342 (Bis-Benzimide, Sigma) for 90 min, and FITC-labeled
bacteria were added. At different time points, 50 mg/ml ethidium
bromide was added for 5 min to stain the cytoplasm of the macro-
phages red. Opsonization was determined by laser scanning confocal
microscopy with a Leica TCS-SP2 confocal scanning head mounted
on a Leica DMRE-7 (SDK) upright microscope (NA = 1.40; Leica
Microsystems Inc., Bannockburn, IL).
Purification of Human Monocytes and Detection
of MMP-1 by Western Blot
Human peripheral blood cells were obtained by leukapheresis from
normal volunteers at the Department of Transfusion Medicine at the
National Institutes of Health. Monocytes were prepared as described
previously (Zhang et al., 1997), and the final preparation contained
greater than 90% monocytes as determined by morphology, nonspe-
cific esterase staining, and flow cytometry. The purification procedure
did not activate the monocytes as demonstrated by the fact that less
than 4% of the cells were IL-2R positive, a sensitive marker of mono-
cyte activation. Purified monocytes (5 3 106/ml) then were stimulated
with 100 ng/ml LPS or LPS premixed with 3.0 mg/ml antibodies (30 min
at 4C) for 36–48 hr as previously described (Zhang et al., 1997). The
supernatant fluids together with BSA (40 mg/ml) were added to cold
ethanol and put at 70C for 15 min. Proteins then were pelleted by
microcentrifugation and lyophilized, and then the resuspended pro-
teins were electrophoresed on a 10% Tris-glycine gradient polyacryl-
amide gel. The proteins then were transferred onto 0.45 mm nitrocellu-
lose, and the blots were incubated overnight with rabbit polyclonal
antibodies against matrix metalloproteinase (MMP-1). Western blots
were analyzed by the addition of Alexa Fluor 680 goat anti-rabbit IgG
(Molecular Probes Inc., Eugene), and the fluorescence was detected
with the Odyssey infrared imaging system (LI-COR, Lincoln, NE).
Statistical Analysis
Data are presented as mean ± SD, and all paired comparisons were
subjected to a two-tailed Student’s t test. Significance was set at a
p value of less than 0.05.
Supplemental Data
The Supplemental Data include one supplemental table and can be
found with this article online at http://www.cellhostandmicrobe/cgi/
content/full/1/1/51/DC1/.
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